Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 2/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15399473 | 1.00 | MCHR1 (0.49) | MCHR1CCR1RAB9ACCR5DHFR | |
| SCHEMBL15400314 | 0.83 | MCHR1 (0.49) | MCHR1CCR1RAB9ACCR5DHFR | |
| SCHEMBL15400315 | 0.83 | MCHR1 (0.49) | MCHR1CCR1RAB9ACCR5DHFR | |
| SCHEMBL15398843 | 0.81 | MCHR1 (0.45) | MCHR1CCR1DHFRDCPSMKNK2 | |
| SCHEMBL15398846 | 0.81 | MCHR1 (0.45) | MCHR1CCR1DHFRDCPSMKNK2 | |
| SCHEMBL13737409 | 0.81 | MCHR1 (0.72) | MCHR1DHFRDCPSMEN1KMT2A | |
| SCHEMBL13737410 | 0.81 | MCHR1 (0.72) | MCHR1DHFRDCPSMEN1KMT2A | |
| SCHEMBL13738034 | 0.78 | KDM4E (0.44) | CCR1RAB9ACCR5MEN1KMT2A | |
| SCHEMBL13737688 | 0.76 | CCR1 (0.52) | MCHR1CCR1RAB9ACCR5MEN1 | |
| SCHEMBL25009544 | 0.69 | MCHR1 (0.39) | MCHR1DHFRDCPSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678329-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8889704-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005213-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MCHR1 1613/4885CCR1 3163/4885RAB9A 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.